REG - Mediclinic Intnl plc - Directorate Change

FD TechnologiesAnnouncement

21/02/2020 11:05

RNS Number : 6654D
Mediclinic International plc
21 February 2020
 


Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company", or the "Group")
 
 
21 February 2020
 
DIRECTORATE CHANGE
 
Following the previous announcement made on 16 January 2020, the Company confirms that Mr Seamus Keating, who serves as an independent non-executive director, will step down from the Board of Mediclinic on 31 March 2020. Mr Keating's intention to retire from the Board was announced subsequent to his appointment as Chief Executive Officer of First Derivatives plc with effect from 15 January 2020. Mr Keating will also resign from all Board subcommittees at that time which include the Audit and Risk Committee, Remuneration Committee and Clinical Performance and Sustainability Committee.
 
The Board will shortly commence a process to identify a suitable replacement for Mr Keating, with an announcement to follow accordingly.
 
This announcement is made in accordance with the requirement of LR 9.6.11.
 
About Mediclinic International plc
 
Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates.
 
The Group's core purpose is to enhance the quality of life.
 
Its vision is to be the partner of choice that people trust for all their healthcare needs.
 
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.
 
As at 1 February 2020, Mediclinic comprised 77 hospitals, five sub-acute hospitals, 14 day case clinics and 22 outpatient clinics. Hirslanden operated 17 hospitals, two day case clinics and three outpatient clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations included 53 hospitals (three of which in Namibia), five sub-acute hospitals and 10 day case clinics (four of which operated by Intercare) across South Africa, and more than 8 500 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 19 outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.
 
The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE Ltd ("JSE") in South Africa and the Namibian Stock Exchange ("NSX") in Namibia.
 
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.
 
For further information, please contact:
 
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)20 7954 9569
 
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
 
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
 
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com 
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAPPUACPUPUGQU